An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity
Cancer Science · 2024-04 · 115 (4) · 1102-1113
DOI: 10.1111/cas.16096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 29.01.2024. Verfasst von Jean-Pierre Bikorimana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, Quebec, Canada. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Cancer Vaccines, Papillomavirus Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Defence Therapeutics, Defense Therapeutics.
Abstract (Originalsprache)
Worldwide prevalence of cervical cancer decreased significantly with the use of human papilloma virus (HPV)‐targeted prophylactic vaccines. However, these multivalent antiviral vaccines are inert against established tumors, which leave patients with surgical ablative options possibly resulting in long‐term reproductive complications and morbidity. In an attempt to bypass this unmet medical need, we designed a new E7 protein‐based vaccine formulation using Accum™, a technology platform designed to promote endosome‐to‐cytosol escape as a means to enhance protein accumulation in target cells. Prophylactic vaccination of immunocompetent mice using the Accum‐E7 vaccine (aE7) leads to complete protection from cervical cancer despite multiple challenges conducted with ascending C3.43 cellular doses (0.5‐, 1.0‐, and 2.0 × 10 6 cells). Moreover, the humoral response induced by aE7 was higher in magnitude compared with naked E7 protein vaccination and displayed potent inhibitory effects on C3.43 proliferation in vitro. When administered therapeutically to animals with pre‐established C3.43 or Tal3 tumors, the vaccine‐induced response synergized with multiple immune checkpoint blockers (anti‐PD‐1, anti‐CTLA4, and anti‐CD47) to effectively control tumor growth. Mechanistically, the observed therapeutic effect requires cross‐presenting dendritic cells as well as CD8 T cells predominantly, with a non‐negligible role played by both CD4 + and CD19 + lymphocytes. good laboratory practice (GLP) studies revealed that aE7 is immunogenic and well tolerated by immunocompetent mice with no observed adverse effects despite the use of a fourfold exceeding dose. In a nutshell, aE7 represents an ideal vaccine candidate for further clinical development as it uses a single engineered protein capable of exhibiting both prophylactic and therapeutic activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, Quebec, Canada.
- Department of Pharmacology and Physiology, Université de Montréal, Montréal, Quebec, Canada.
- Department of Molecular Biology, Université de Montréal, Montréal, Quebec, Canada.
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
- Defence Therapeutics Inc., Vancouver, British Columbia, Canada.
ORCID-Profile: Moutih Rafei
Förderung
- Defence Therapeutics
- Defense Therapeutics
Zitieren
APA
Bikorimana, J. P., Abusarah, J., Gonçalves, M., Farah, R., Saad, W., Talbot, S., Stanga, D., Beaudoin, S., Plouffe, S., & Rafei, M. (2024). An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity. Cancer Science, 115(4), 1102-1113. https://doi.org/10.1111/cas.16096
Vancouver
Bikorimana JP, Abusarah J, Gonçalves M, Farah R, Saad W, Talbot S, et al. An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity. Cancer Science. 2024;115(4):1102-1113. doi:10.1111/cas.16096
BibTeX
@article{Bikorimana2024,
author = {Bikorimana, Jean-Pierre and Abusarah, Jamilah and Gonçalves, Marina and Farah, Roudy and Saad, Wael and Talbot, Sebastien and Stanga, Daniela and Beaudoin, Simon and Plouffe, Sebastien and Rafei, Moutih},
title = {An engineered Accum‐E7 protein‐based vaccine with dual anti‐cervical cancer activity},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {4},
pages = {1102--1113},
doi = {10.1111/cas.16096}
}
EUVIMED